ID   AP-1060
AC   CVCL_1807
DR   BioSample; SAMN03473492
DR   Cosmic; 2750857
DR   DSMZ; ACC-593
DR   DSMZCellDive; ACC-593
DR   Wikidata; Q54750179
RX   PubMed=15116119;
RX   PubMed=29119387;
CC   Doubling time: ~48 hours (PubMed=15116119); ~80-100 hours (DSMZ=ACC-593).
CC   Sequence variation: Gene deletion; HGNC; HGNC:12796; WT1; Zygosity=Homozygous (PubMed=29119387).
CC   Sequence variation: Gene fusion; HGNC; HGNC:3495; ETV6 + HGNC; HGNC:8033; NTRK3; Name(s)=ETV6-NTRK3, TEL-TRKC (PubMed=29119387).
CC   Sequence variation: Gene fusion; HGNC; HGNC:9113; PML + HGNC; HGNC:9864; RARA; Name(s)=PML-RARA (PubMed=15116119).
CC   Sequence variation: Mutation; HGNC; HGNC:9864; RARA; Simple; p.Pro408Ser (c.1222C>T); Zygosity=Unspecified; Note=Equivalent to p.Pro900Ser in the PML-RARA fusion protein (PubMed=15116119).
CC   Omics: Variations; Array-based CGH.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): DSMZ=ACC-593
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 8,12
ST   D16S539: 10,11
ST   D18S51: 14,19
ST   D19S433: 14
ST   D21S11: 29,32.2
ST   D2S1338: 17,23
ST   D3S1358: 14,16
ST   D5S818: 12
ST   D7S820: 10,11
ST   D8S1179: 12
ST   FGA: 19,24
ST   Penta D: 9,13
ST   Penta E: 5,12
ST   TH01: 9.3
ST   TPOX: 8,11
ST   vWA: 14,17
DI   NCIt; C3182; Acute promyelocytic leukemia with PML-RARA
DI   ORDO; Orphanet_520; Acute promyelocytic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 25
//
RX   PubMed=15116119; DOI=10.1038/sj.leu.2403372;
RA   Sun Y., Kim S.H., Zhou D.-C., Ding W., Paietta E.M., Guidez F.,
RA   Zelent A., Ramesh K.H., Cannizzaro L.A., Warrell R.P. Jr.,
RA   Gallagher R.E.;
RT   "Acute promyelocytic leukemia cell line AP-1060 established as a
RT   cytokine-dependent culture from a patient clinically resistant to
RT   all-trans retinoic acid and arsenic trioxide.";
RL   Leukemia 18:1258-1269(2004).
//
RX   PubMed=29119387; DOI=10.1007/s13402-017-0356-2;
RA   Chen S.-N., Nagel S., Schneider B., Dai H.-P., Geffers R., Kaufmann M.,
RA   Meyer C., Pommerenke C., Thress K.S., Li J., Quentmeier H.,
RA   Drexler H.G., MacLeod R.A.F.;
RT   "A new ETV6-NTRK3 cell line model reveals MALAT1 as a novel
RT   therapeutic target -- a short report.";
RL   Cell. Oncol. (Dordr.) 41:93-101(2018).
//